Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple bedside panel make intensive care feel more human?

NCT ID NCT07830043

NEW Symptom relief Sponsor: University of Sao Paulo General Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 21, 2026 · Last updated Sep 21, 2026

Summary

Intensive care units focus on complex medical care, which can push aside who a patient is as a person. This trial tests a low-cost panel placed near each patient's bed where the care team, patient, and family record how the patient likes to be addressed, their interests, and what matters to them. Staff at six Brazilian ICUs receive training to use that information in daily care. Researchers compare family satisfaction, patient-reported communication, and family anxiety and depression during standard care versus when the panel is in use.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a structured bedside 'Patient as a Person' panel completed by the care team with the patient and family, plus staff training
What this could lead to
If it helps, this could give hospitals a low-cost way to make intensive care feel more personal and improve how families experience a loved one's stay.
What could go wrong
Satisfaction scores can rise for reasons unrelated to the panel, and results from six Brazilian ICUs may not carry over to other hospitals or health systems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 966 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient admitted to a participating ICU for more than 48 hours. * Patient aged 18 years or older. * Patient's family member or legally designated surrogate aged 18 years or older, and identifiable at the time of enrollment. * Patient and/or family member/surrogate able to speak and understand Portuguese. * Signature of the Informed Consent Form (ICF) by the family member or surrogate after 48 hours of ICU admission, and by the patient once conscious and oriented (also after 48 hours of ICU admission). Exclusion Criteria: * ICU stay of 48 hours or less. * No identifiable family member or legally designated surrogate. * Patient or family member/surrogate under 18 years of age. * Unable to speak or understand Portuguese. * Pregnant patient. * Patient deprived of liberty (incarcerated). * Refusal to sign the Informed Consent Form.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Critical care, intensive care are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Critical Illness

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Critical care, intensive care Critical illness Family satisfaction

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Clinical Hospital of the University of São Paulo Medical School- Central Institute

    São Paulo, São Paulo, 05403-000, Brazil

  • Monte Klinikum Hospital

    Fortaleza, Ceará, 60160-140, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.